Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — you cannot reliably dose 5mg from a 7.5mg Mounjaro KwikPen. Each Mounjaro pen is pre-set by the manufacturer to deliver one fixed dose per injection; there is no dial or mechanism that lets you adjust the amount released. If your prescription says 5mg, you need a 5mg pen. This matters both for accuracy and for your safety, and the NHS tirzepatide medicines guide is clear that Mounjaro is used exactly as prescribed. A question our prescribers hear most weeks is whether a higher-strength pen can stretch further or be used at a lower dose — the short answer is no, and the detail below explains exactly why.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro KwikPen is not an adjustable insulin-style pen. It is a single-use, spring-loaded auto-injector pre-filled with enough solution for four weekly doses at one fixed concentration. When you press the button, the mechanism releases the entire pre-measured volume for that strength. There is no window, no dial and no way to stop the delivery partway through to capture less medicine.
Each pen in the range (2.5mg through to 15mg) contains a different concentration of tirzepatide per dose. A 7.5mg pen holds 7.5mg of tirzepatide per injection, calibrated to that volume. Even if you could somehow interrupt the injection, the dead-space in the needle and the mechanics of the plunger mean the volume you'd receive would be unpredictable. You would not get 5mg. You might get more, you might get less.
The Mounjaro SmPC on the eMC is unambiguous: administer the pen as instructed, at the prescribed dose, once weekly. Nothing in the licensed instructions supports partial delivery or strength substitution.
Getting more tirzepatide than prescribed is not a neutral mistake. Dose-related side effects (nausea, vomiting, diarrhoea, reflux) are most common after starting or increasing, precisely because the body needs time to adjust. Receiving 7.5mg when your prescription says 5mg skips that adjustment. For some people that gap is clinically significant; for others it might seem fine, but there is no way to know in advance.
Going the other way, receiving a smaller unpredictable amount, undermines the steady pharmacokinetics that make tirzepatide work over a weekly cycle. The titration schedule exists for good reasons, and tinkering with it outside clinical supervision pulls you outside the evidence base entirely.
There is also a practical concern: using a pen in any way other than as instructed can damage the device, introduce air into the mechanism, or lead to incomplete needle retraction. If you are unsure whether a pen has delivered correctly, the right step is to contact your prescriber or pharmacist rather than attempt a second injection.
If you are currently on 5mg and your prescriber has decided you are ready to move to 7.5mg, that decision comes with a new prescription for 7.5mg pens. The two doses are not interchangeable in either direction. Similarly, stepping back down to a lower strength is sometimes clinically appropriate, but it requires a prescriber to issue a new prescription for the lower-strength pen, not an attempt to use the higher one at reduced volume.
The titration schedule for Mounjaro starts at 2.5mg and moves upward in 4-week steps as clinically directed. The detail of what the 5mg stage involves and how long people typically stay there is worth reading if you are currently at that point. What does not change is the principle: each rung requires the pen matched to it.
For context on jumping steps on Mounjaro, the same logic applies in reverse, the clinical case for that would have to be made by your prescriber based on your response, not by using a stronger pen and guessing. The dose schedule is a clinical tool, not a suggestion.
Supply can be variable. If a 5mg pen is temporarily out of stock and all you have is a 7.5mg pen, the answer is not to try to split the dose. The right steps are: contact your pharmacy as soon as possible; ask your prescriber whether to delay your injection briefly while the correct pen is sourced, or whether an alternative arrangement is clinically appropriate.
Guidance on timing adjustments for Mounjaro covers what a short delay means in practice, in most cases a few days' variance is manageable, but that is a clinical call, not a self-management one. Staying on 7.5mg when prescribed 5mg, even temporarily, is not a safe workaround.
If you are exploring private Mounjaro treatment and want to understand how prescription and supply work at a regulated pharmacy, the treatment options and consultation page explains the process. Every repeat order at nume goes through clinical re-review, which is exactly the kind of oversight that catches supply questions before they become problems. You can also read more about how Mounjaro works as a treatment, and for broader context on the private route, the guide to obtaining Mounjaro through a regulated online pharmacy covers what legitimate supply should look like.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.